Catalyst Health Economics Consultants

Depression

1. Economic impact of using mirtazapine in the management of moderate and severe depression in France.

Presented at the 10th ECNP Congress, Vienna, September 1997.

2. Economic impact of using mirtazapine in the management of moderate and severe depression in Austria.

Presented at the XXIst CINP Congress, Glasgow, July 1998 and the 11th ECNP Congress, Paris, October 1998.

3. Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France.

Authors: MCJ Brown, JMT van Loon & JF Guest.
Source: European Journal of Psychiatry 1999; 13(4): 197-208.

View Abstract

4. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria.

Authors: MCJ Brown, AA Nimmerrichter & JF Guest.
Source: European Psychiatry 1999; 14: 230-244.

View Abstract


5. Cost-effectiveness of mirtazapine in the management of moderate and severe depression in the UK.

Presented at the 12th ECNP Congress, London, September 1999.

6. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.

Authors: J Borghi & JF Guest.
Source: European Psychiatry 2000; 15: 378-387.

View Abstract

7. Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France.

Authors: MCJ Brown, JMT van Loon & JF Guest.
Source: European Journal of Psychiatry 2000; 14(1): 15-25.

View Abstract

8. Do antidepressants reduce the burden imposed by depression on employers?

Authors: MJ Greener and JF Guest.
Source: CNS Drugs 2005; 19( 3): 253-264

View Abstract


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018